NCT05655325 · RECRUITING
Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity
This trial is testing whether six months of home-based walking improves memory and brain structure and function in older adults who have both chronic kidney disease (stages 3-4) and mild cognitive impairment. Participants are compared to a group receiving health education instead of exercise. This is a Phase N/A behavioral trial, meaning it is evaluating a lifestyle intervention rather than a drug, and it is not yet proven or approved as a treatment approach.
Eligibility criteria
Inclusion Criteria: * • Diagnosed stage 3-4 chronic kidney disease (CKD, estimated glomerular filtration rate (eGFR) \<60 to 20 ml/min); * >55 yrs of age * Mild cognitive impairment (18-26 on the MOCA) * ability to undergo an MR * no history of major head trauma (No head trauma/concussion with loss of consciousness) * Speaks, reads, writes English Exclusion Criteria: * • Diagnosed Dementia or a Clinical Dementia Rating Scale score of \<2, or a MOCA of \<18 * Participating in a supervised exercise program with intent to increase fitness levels 3 days/week, * Requires assistive ambulation * Limited exercise capacity due to claudication; unstable angina, severe arthritis, extreme dyspnea on exertion, unstable coronary artery disease * Class III-IV heart failure * History of uncontrolled sustained arrhythmias, severe/symptomatic aortic or mitral stenosis, hypertrophic obstructive cardiomyopathy, severe pulmonary hypertension, active myocarditis/pericarditis, thrombophlebitis, and recent systemic/pulmonary embolus * Resting systolic BP >200 mmHg or resting diastolic BP >110 mmHg * Any unforeseen illness or disability that would preclude cognitive testing or exercise training * One or more contraindication for MRI; cardiac pacemaker, aneurysm clip, cochlear implants, shrapnel, history of metal fragments in eyes, neurostimulators, diagnosed claustrophobia (MRI only) * Any self-reported major psychiatric disorders requiring medical therapy (e.g. schizophrenia, bipolar disorder). * Self-reported new diagnosis of clinical depression within 3 months of enrollment or unstable clinical depression requiring medication adjustment within 3 months of enrollment
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-13